Certara (NASDAQ: CERT) — Perfil da empresa, notícias e dados financeiros
Certara accelerates drug discovery with biosimulation software and services for the biopharmaceutical industry.
Certara
Certara (NASDAQ:CERT) is a global biosimulation company that plays a pivotal role in the acceleration of drug discovery and development. It specializes in creating software and services that support decision-making processes of the biopharmaceutical and healthcare sectors. The company's range of projects encompasses regulatory science, drug development, and the application of quantitative systems pharmacology (QSP) to increase the efficiency and success rate of bringing new therapies to market. Certara's objectives are closely tied to improving human health through innovation, reducing the time and cost associated with drug development, and enhancing decision-making in complex scenarios. This approach not only benefits the pharmaceutical industry but also aims to have a direct positive impact on patient outcomes.
Resumo
Operações
Produtos e/ou serviços de Certara
- Biosimulation: Leveraging virtual patient populations and simulations to predict how drugs behave in different demographic groups.
- Regulatory Science: Providing expertise and software to streamline regulatory submissions and approvals for pharmaceutical products.
- PBPK Modeling Software: Advanced platforms for physiologically based pharmacokinetic modeling, aiding in drug discovery and development.
- Quantitative Systems Pharmacology (QSP): Integrating computational modeling and experimental data to explore complex biological systems and drug effects.
- Market Access and HEOR: Offering evidence-based services to demonstrate product value and support global market access strategies.
- Clinical Trial Data Services: Utilizing sophisticated software to analyze and manage clinical trial data, optimizing trial outcomes.
equipe executiva do Certara
- Robert P. AspburyPresident of Certara Predictive Technologies
- Leif E. PedersenSenior Advisor
- Adrian K. McKemeyPresident of Drug Development Solutions
- Jon ResnickCEO & Director
- Julien PerrierPresident & Chief Commercial Officer
- Faiz MohammedInterim CFO, Senior VP of Finance, Treasurer and Principal Financial & Accounting Officer
- Christopher BoutonChief Technology Officer & Chief AI Officer
- Eric JahnChief Information Officer
- Daniel D. CorcoranSenior VP, General Counsel & Secretary
- Ron DiSantisSenior Vice President of Corporate Development
Principais indicadores financeiros
Resultados divulgados pela Certara, em USD.
- Cap. de mercado
- 1,8 bi
- Receita (TTM)
- 421,7 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.1
- Dividend yield
- —
- Margem de lucro
- -16.2%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 418,8 mi | 21 mi | -1,6 mi | |
| 385,1 mi | -1,7 mi | -12,1 mi | |
| 354,3 mi | -40,8 mi | -55,4 mi | |
| 335,6 mi | 32,5 mi | 14,7 mi |